Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
▼
$329.99
$12.58B1.18832,048 shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+82.49%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
▼
$329.99
$12.58B1.18832,048 shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+82.49%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.00
Hold$14.560.50% Upside
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$634.21M7.17$0.06 per share234.67$0.87 per share16.66
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%N/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
1.43
2.84
1.88
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31

Institutional Ownership

CompanyInstitutional Ownership
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.20%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
13.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480314.00 million307.09 millionOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable

Recent News About These Companies

Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
December 19, 2025  |  fiercebiotech.comF
Karuna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s Psychosis
August 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/karuna-therapeutics-phase-3-study-on-karxt-a-potential-game-changer-for-alzheimers-psychosis-3?utm_source=marketbeat.com&utm_medium=referral
Karuna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s Psychosis
July 17, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/karuna-therapeutics-phase-3-study-on-karxt-a-potential-game-changer-for-alzheimers-psychosis-2?utm_source=marketbeat.com&utm_medium=referral
Karuna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s Psychosis
July 4, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/karuna-therapeutics-phase-3-study-on-karxt-a-potential-game-changer-for-alzheimers-psychosis?utm_source=marketbeat.com&utm_medium=referral
Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT Study
June 27, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/karuna-therapeutics-advances-alzheimers-psychosis-treatment-with-karxt-study?utm_source=marketbeat.com&utm_medium=referral
Seaport loads up $225M series B to continue Karuna veterans' voyage to clinical milestones
October 21, 2024  |  fiercebiotech.comF
This FDA-approved drug promises a new way to treat schizophrenia
September 30, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/this-fda-approved-drug-promises-a-new-way-to-treat-schizophrenia/ar-AA1rhzq1
FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try
September 27, 2024  |  endpts.comE
End­points 11 win­ner Sea­port Ther­a­peu­tics: The Karuna team is back with an­oth­er big bet in neu­ro­science
September 27, 2024  |  endpts.comE
BMS wins approval for schizophrenia drug acquired from Karuna
September 27, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/bms-wins-approval-for-schizophrenia-drug-acquired-from-karuna/ar-AA1rlDRT
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
September 27, 2024  |  fiercepharma.comF
Bristol Myers to Purchase Karuna
September 13, 2024  |  msn.comhttps://www.msn.com/en-us/sports/nfl/indexnowdelete/ar-AA1lUq62
BMS wagers $14bn on Karuna’s schizophrenia drug
July 25, 2024  |  pharmaphorum.comP
Ex-Karuna team launch Seaport with $100m for psychiatry meds
May 10, 2024  |  pharmaphorum.comP
S&P 500 Q1 earnings estimated growth improves; stocks up for week
April 26, 2024  |  investing.comhttps://www.investing.com/news/stock-market-news/sp-500-q1-earnings-estimated-growth-improves-stocks-up-for-week-3401559
Bristol Myers posts quarterly loss, lays out $1.5 billion cost-saving plan
April 25, 2024  |  investing.comhttps://www.investing.com/news/stock-market-news/bristol-myers-posts-quarterly-loss-revenue-rises-5-3397368
After Karuna's acquisition, former CEO lands new gig at Cambridge biotech
April 22, 2024  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2024/04/22/karuna-ceo-lands-new-gig-leading-cambridge-biotech.html
Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs
April 11, 2024  |  biospace.comB
Seaport Therapeutics has $100 million to develop new ways to treat mental disorders
April 9, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/seaport-therapeutics-has-100-million-to-develop-new-ways-to-treat-mental-disorders/ar-BB1lllGe
Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells
April 9, 2024  |  statnews.comS

New MarketBeat Followers Over Time

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Karuna Therapeutics stock logo

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas